Di­a­betes drugs

Australian Women’s Weekly NZ - - HEALTH -

Al­most a decade ago, a new wave of di­a­betes drugs hit the phar­ma­cies, with prom­ises to lower blood-sugar lev­els. Yet they failed to alle­vi­ate one of the big­gest con­cerns for Type 2 di­a­betes suf­fer­ers – their in­creased risk of car­dio­vas­cu­lar disease (CVD). Last year, two new drugs showed signs of slash­ing mor­tal­ity rates from di­a­betes re­lated CVD. Em­pagliflozin mod­i­fies the pro­gres­sion of heart disease by work­ing with the kid­ney, while li­raglu­tide has a com­pre­hen­sive ef­fect on many or­gans. In light of these re­sults, a distin­guished panel of doc­tors and re­searchers, as­sem­bled by the Cleve­land Clinic in the US, pre­dicts that, this year, there will be a to­tal shift in the line-up of drugs pre­scribed for di­a­betes – as well as a wave of re­search into new av­enues tar­get­ing Type 2 di­a­betes and its re­lated diseases.

Newspapers in English

Newspapers from New Zealand

© PressReader. All rights reserved.